Zhenyi Medical Establishes Xiamen Subsidiary to Accelerate Innovation and Commercialization in Structural Heart Disease

In September 2025, Jiangsu Trulive Medtech Co., Ltd. ("Trulive"), in which C&D Emerging Investment and its partner Ji Feng Capital have jointly invested, established a research and innovation center, a professional education center, and a marketing center in Xiamen to accelerate the R&D and commercialization process of innovative products for structural heart disease.

Trulive, founded in 2019, is a specialized cardiovascular interventional medical device platform enterprise focused on solving blood flow issues. The company has developed a one-stop toolbox for cardiovascular treatment, offering solutions for various blood flow problems, including valve management — the treatment of heart valve diseases to ensure correct blood flow direction; clearance — the treatment of vascular stenosis or occlusion to ensure smooth blood flow; and shunting — the intervention for heart failure to relieve pathological high pressure.

C&D Emerging Investment has always adhered to the concept of "investing early, investing small, investing long-term, and investing in hard technology." As early as 2021, it participated in Trulive's Series A financing and completed two follow-up investments in 2022 and 2023. When C&D Emerging Investment first invested in Trulive, the company had fewer than 30 employees, and all products were still in the early stages of development, not yet undergoing human trials. After four years of support and partnership, Trulive has made rapid progress in product development, quickly emerging as a "dark horse" in the field of cardiovascular interventional treatment and achieving significant results. Currently, the company has obtained Class III medical device registration certificates from China for three core products, with several other products in the clinical trial stage, leading in progress within China. In the coming years, Trulive is set to enter a commercial harvest period. The establishment of the Xiamen subsidiary will allow Trulive to directly benefit from Xiamen's industrial and clinical resources, promoting faster and better development through the integration of medicine and engineering, professional education, and commercial promotion.

Trulive's chairman Wen Jing stated: Trulive's development is inseparable from the support of Xiamen. Since 2021, it has received multiple rounds of investment from C&D Emerging Investment, and last year gained backing from Xiamen Torch High-tech Investment. This year, it received another round of support from the Xiamen Cardiovascular Industry Fund and Xiamen Industrial Investment. Ultimately, with the promotion of all shareholders in Xiamen, Trulive successfully established its long-planned R&D, education, and marketing center in Xiamen. This not only marks a historic upgrade to Trulive’s industrial R&D system but also serves as a key engine for the company’s overall strategy of "rooted in China, facing the world." This collaboration will provide new opportunities for Trulive to further implement professional education, expand market space, and deepen industrial layout. The project benefits from Xiamen's excellent business environment and biomedical industry foundation. In the future, the company will further leverage Xiamen's industrial and geographical advantages, continue to deepen medical-engineering cooperation, promote the deep integration of clinical practice and scientific research innovation, accelerate technological breakthroughs and the transformation of results, and contribute to the rapid development of Xiamen's high-end medical device innovation field.

As a wholly-owned subsidiary of Xiamen's state-owned enterprise, C&D Group, C&D Emerging Investment has always regarded promoting the industrial upgrading of Xiamen and introducing new momentum for regional economic development as an important mission. Subsequently, C&D Emerging Investment will continue to work with its partners, using long-term capital and industrial resources to deeply empower entrepreneurs, utilizing technology to drive innovation implementation, promote industrial upgrading, and create value, contributing to the realization of high-quality economic development and social progress.